Skip to content
Peptigraph home

ARA-290

EPO-derived peptide. ARA-290 is not FDA approved for any use.

Also called:cibinetide
Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated Strongest evidence: Human RCT evidence, 4 of 4
StatusNot FDA approved · research chemicalWADA status unclearFull legal history

Key facts

Class
EPO-derived peptide
Also called
cibinetide
Half-life
~2 min
plasma (route not stated in abstract), in people · Pharmacology & therapeutics 2015, PMID 25728128
FDA status
Not approved
research chemical
WADA
Unclear
Not named on the 2026 list
Everything on ARA-290

ARA-290 guides

Evidence at a glance

Human and animal counts are PubMed records from our evidence ledger (search counts, not studies we reviewed). The grade is the strongest design among the studies we summarised for that goal: a human randomized trial outweighs any number of animal studies.

ARA-290: studies by condition
ConditionHuman studiesAnimal studiesStudies we summarisedEvidence grade
NeuropathyNot in our ledgerNot in our ledger5Human RCT evidence, 4 of 4Investigative ophthalmology & visual science 2017, PMID 28475703

Grades follow our evidence scale. Summarised studies come from our evidence file, each quote checked against the abstract or label.

ARA-290 (cibinetide): an erythropoietin-derived peptide that does not raise red cells

Abstracts describe ARA-290 as a nonerythropoietic peptide engineered from erythropoietin.[9]

In mice with genetic diabetes, activating the EPOR-β common receptor complex with cibinetide ameliorated impaired wound healing.[10]

A review reports a plasma half-life of about 2 minutes, with sustained biological effects seen in animal models and clinical trials.[5]

Small trials in nerve disease, with mixed readouts

In a placebo-controlled trial in sarcoidosis patients with small fibre neuropathy symptoms, the ARA 290 group improved more than placebo on the SFNSL symptom score at week 4. Mean pain (BPI) and fatigue (FAS) scores improved significantly but equally in both groups.[11]

In a 28-day phase 2b trial in sarcoidosis-associated small nerve fibre loss, the placebo-corrected change in corneal nerve fibre area was significant only in the 4 mg group (P = 0.012).[4]

In a phase 2 trial in diabetic macular edema, there was no mean improvement in visual acuity (BCVA) or central retinal thickness, though NEI VFQ-25 composite scores improved.[12]

In 36 healthy participants given ARA290 (2mg) or placebo, no effects were observed on mood and affective symptoms. The authors say the results do not unequivocally support an antidepressant-like profile.[13]

Regulatory path and sport

Drugs@FDA lists no ARA-290 product.[2]

FDA's compounding list names cibinetide (ARA-290) in its bulk-substance categories.[3]

WADA bans innate repair receptor agonists such as asialo EPO and carbamylated EPO (S2.1.5). ARA-290 is not named there.[1]

Common questions

Is ARA-290 FDA approved?

No. ARA-290 is not FDA approved for any use.

What is ARA-290?

A peptide engineered from erythropoietin, also called cibinetide; abstracts describe it as nonerythropoietic.[9]

What does ARA-290 do?

In a small randomized trial it improved neuropathy symptom scores in sarcoidosis patients.[11]

Is there an ARA-290 nasal spray?

The animal work in the cached literature used intraperitoneal injections in rats and mice; no nasal-spray study was found.[14]

Sources

  1. 1World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  2. 2United States: No FDA-approved product found: Drugs@FDA (openFDA) search for active ingredient "ARA-290" returned no matches on 2 Oct 2026.U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
  3. 3US compounding: Cibinetide (ARA-290) is listed in FDA's 503A category 3 (nominated without adequate support).U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  4. 4Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain.Investigative ophthalmology & visual science · 2017PMID 28475703Accessed 2 Oct 2026
  5. 5Flipping the molecular switch for innate protection and repair of tissues: Long-lasting effects of a non-erythropoietic small peptide engineered from erythropoietin.Pharmacology & therapeutics · 2015PMID 25728128Accessed 2 Oct 2026
  6. 6PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) (75 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (sarcoidosis[tiab] OR neuropath*[tiab] OR patients[tiab] OR randomized[tiab]) (29 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: (ARA-290[tiab] OR ARA290[tiab] OR cibinetide[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9ARA 290, a nonerythropoietic peptide engineered from erythropoietin, improves metabolic control and neuropathic symptoms in patients with type 2 diabetes.Molecular medicine (Cambridge, Mass.) · 2015PMID 25387363Accessed 2 Oct 2026
  10. 10Activation of the EPOR-β common receptor complex by cibinetide ameliorates impaired wound healing in mice with genetic diabetes.Biochimica et biophysica acta. Molecular basis of disease · 2018PMID 29223734Accessed 2 Oct 2026
  11. 11Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study.Molecular medicine (Cambridge, Mass.) · 2012PMID 23168581Accessed 2 Oct 2026
  12. 12A Phase 2 Clinical Trial on the Use of Cibinetide for the Treatment of Diabetic Macular Edema.Journal of clinical medicine · 2020PMID 32674280Accessed 2 Oct 2026
  13. 13Testing the antidepressant properties of the peptide ARA290 in a human neuropsychological model of drug action.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2015PMID 26431906Accessed 2 Oct 2026
  14. 14ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain: an experimental study in rats and β-common receptor knockout mice.Anesthesiology · 2011PMID 21873879Accessed 2 Oct 2026

Found an error? Report a correction.